Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is a 3-part, first-in-human study to evaluate the safety, tolerability and
pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy
male subjects. In part 1, subjects will receive a single dose of XNW4107. In part 2, subjects
will receive XNW4107 for 7 days. In Part 3, subjects will receive XNW4107 in combination with
imipenem/cilastatin for 14 days.